ES2072163T3 - Compuestos de inclusion de acido 5,10-metilenotetrahidrofolico y ciclodextrina. - Google Patents

Compuestos de inclusion de acido 5,10-metilenotetrahidrofolico y ciclodextrina.

Info

Publication number
ES2072163T3
ES2072163T3 ES93110567T ES93110567T ES2072163T3 ES 2072163 T3 ES2072163 T3 ES 2072163T3 ES 93110567 T ES93110567 T ES 93110567T ES 93110567 T ES93110567 T ES 93110567T ES 2072163 T3 ES2072163 T3 ES 2072163T3
Authority
ES
Spain
Prior art keywords
acid
cyclodextrin
tethydropholic
methylene
inclusion compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93110567T
Other languages
English (en)
Inventor
Hans Rudolf Muller
Josef Conti
Martin Ulmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eprova AG
Original Assignee
Eprova AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eprova AG filed Critical Eprova AG
Application granted granted Critical
Publication of ES2072163T3 publication Critical patent/ES2072163T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ink Jet (AREA)
  • Ink Jet Recording Methods And Recording Media Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A NUEVOS COMPUESTOS DE INCLUSION DE CICLODEXTRINA DEL ACIDO 5,10-METILENOTETRAHIDROFOLICO. LA SORPRENDENTE BUENA ESTABILIDAD DEL COMPUESTO POSIBILITA POR PRIMERA VEZ SU APLICACION FARMACEUTICA. LA INVENCION SE REFIERE ADEMAS A UN PROCEDIMIENTO PARA PRODUCIR LAS SUBSTANCIAS MENCIONADAS Y SU APLICACION PARA LA PRODUCCION DE MEDICAMENTOS.
ES93110567T 1992-07-13 1993-07-02 Compuestos de inclusion de acido 5,10-metilenotetrahidrofolico y ciclodextrina. Expired - Lifetime ES2072163T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH2192/92A CH684644A5 (de) 1992-07-13 1992-07-13 5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.

Publications (1)

Publication Number Publication Date
ES2072163T3 true ES2072163T3 (es) 1995-07-01

Family

ID=4228046

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93110567T Expired - Lifetime ES2072163T3 (es) 1992-07-13 1993-07-02 Compuestos de inclusion de acido 5,10-metilenotetrahidrofolico y ciclodextrina.

Country Status (18)

Country Link
US (1) US5455236A (es)
EP (1) EP0579996B1 (es)
JP (1) JP2667354B2 (es)
KR (1) KR100217788B1 (es)
CN (1) CN1032901C (es)
AT (1) ATE121949T1 (es)
AU (1) AU661591B2 (es)
CA (1) CA2100126C (es)
CH (1) CH684644A5 (es)
DE (1) DE59300176D1 (es)
DK (1) DK0579996T3 (es)
ES (1) ES2072163T3 (es)
FI (1) FI933151A (es)
HU (2) HU212665B (es)
NO (1) NO303715B1 (es)
RU (1) RU2135519C1 (es)
TW (1) TW379142B (es)
ZA (1) ZA934907B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CN1095472C (zh) * 2000-04-17 2002-12-04 上海复康医药科技发展有限公司 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物
CN1748704B (zh) * 2004-09-15 2011-05-04 尼普洛株式会社 注射用水溶液制剂及其稳定化方法
ATE530188T1 (de) * 2007-03-02 2011-11-15 Univ Wollongong Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
CN101235102B (zh) * 2008-02-18 2010-11-03 南昌航空大学 一种叶酸偶联羟丙基壳聚糖纳米微粒的制备方法
CN102000345A (zh) * 2010-11-16 2011-04-06 广西大学 包合态的叶酸/β-环糊精组合物及其制备方法
CN102258788B (zh) * 2011-06-13 2012-11-07 南开大学 一种靶向传递阿霉素抗癌药的组装体及其制备方法
EP2837631A1 (en) * 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid
RU2537246C1 (ru) * 2013-10-17 2014-12-27 Федеральное государственное бюджетное учреждение "Научный центр клинической и эскпериментальной медицины" Сибирского отделения Российской академии медицинских наук ФГБУ "НЦКЭМ" СО РАМН Способ получения биотинилированного производного окисленного декстрана
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
JP7232815B2 (ja) 2017-08-16 2023-03-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ５，１０－メチレン－（６ｒ）－テトラヒドロ葉酸を含む安定な凍結乾燥物
CN112089848A (zh) * 2020-10-27 2020-12-18 浙江诺得药业有限公司 叶酸的环糊精包合物及其制备方法
WO2023237480A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Stable pharmaceutical compositions comprising 5,10-methylene-(6r)-tetrahydrofolic acid and nacl
WO2023237482A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Concentrated solutions comprising sodium 5,10-methylene-(6r)- tetrahydrofolate
WO2023237483A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Concentrated solutions comprising 5,10-methylene-(6r)-tetrahydrofolic acid
WO2023237485A1 (en) 2022-06-08 2023-12-14 Merck Patent Gmbh Stable lyophilisates comprising 5,10-methylene-(6r)-tetrahydrofolic acid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4350659A (en) * 1981-07-30 1982-09-21 Corning Glass Works Stabilization of sensitive biologically active intermediate metabolites such as folic acid derivatives
JPS602775B2 (ja) 1981-08-28 1985-01-23 富士通株式会社 モニタ機能付大規模集積回路及びその製造方法
JPS59175432A (ja) * 1983-03-25 1984-10-04 Yatoron:Kk ジヒドロ葉酸溶液の安定化方法
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
GB8621268D0 (en) * 1986-09-03 1986-10-08 Univ Strathclyde Separation of substances
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
NL8901432A (nl) 1989-06-06 1991-01-02 Pharmachemie Bv Bij koelkasttemperatuur stabiele waterige folinaatoplossing, alsmede werkwijze ter bereiding daarvan.
CA2021042A1 (en) 1989-07-21 1991-01-22 Fabrizio Marazza Salts of n ,n -methylene-5,6,7,8-tetrahydrofolic acid
DE69021673T2 (de) 1989-08-21 1996-05-02 American Cyanamid Co Stabile injizierbare pharmazeutische Formulation mit Folinsäure und Leukovorinsalze und Verfahren.
IT1237509B (it) 1989-10-31 1993-06-08 Magis Farmaceutici Complessi con le ciclodestrine indicati per il trattamento di tutte leforme anemiche da carenza di folati, loro preparazione e relative composizioni farmaceutiche
CH680731A5 (es) * 1990-04-12 1992-10-30 Sapec Fine Chemicals
WO1991017660A1 (en) 1990-05-11 1991-11-28 Spears Colin P 5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
US5153309A (en) * 1990-07-27 1992-10-06 The United States Of America As Represented By The Department Of Health And Human Services Process of making tetrahydropteroylpoly-l-glutamic acid derivatives
CH681303A5 (es) 1991-01-16 1993-02-26 Eprova Ag
KR100207360B1 (ko) * 1991-06-14 1999-07-15 돈 더블유. 슈미츠 이미다조[1,5,-a]퀸옥살린

Also Published As

Publication number Publication date
RU2135519C1 (ru) 1999-08-27
NO932517L (no) 1994-01-14
AU4187093A (en) 1994-01-20
HU211484A9 (en) 1995-11-28
HU212665B (en) 1996-09-30
DE59300176D1 (de) 1995-06-08
US5455236A (en) 1995-10-03
TW379142B (en) 2000-01-11
EP0579996B1 (de) 1995-05-03
FI933151A (fi) 1994-01-14
KR100217788B1 (ko) 1999-09-01
CA2100126A1 (en) 1994-01-14
JP2667354B2 (ja) 1997-10-27
ZA934907B (en) 1994-02-09
NO932517D0 (no) 1993-07-09
EP0579996A1 (de) 1994-01-26
CN1032901C (zh) 1996-10-02
ATE121949T1 (de) 1995-05-15
KR940002301A (ko) 1994-02-17
AU661591B2 (en) 1995-07-27
JPH0718084A (ja) 1995-01-20
CN1081688A (zh) 1994-02-09
HU9301990D0 (en) 1993-09-28
CH684644A5 (de) 1994-11-15
NO303715B1 (no) 1998-08-24
HUT65714A (en) 1994-07-28
FI933151A0 (fi) 1993-07-09
DK0579996T3 (da) 1995-07-10
CA2100126C (en) 1998-05-05

Similar Documents

Publication Publication Date Title
ES2072163T3 (es) Compuestos de inclusion de acido 5,10-metilenotetrahidrofolico y ciclodextrina.
DE3775882D1 (de) Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeuren ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen.
HU9401445D0 (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
DE69027440D1 (de) Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
FI953139A0 (fi) Atovakonia käsittäviä farmaseuttisia koostumuksia
AU1331588A (en) Method for treatment of alcohol abuse
FI894899A0 (fi) Menetelmä dispergoituvan kiinteän lääkeainekoostumuksen valmistamiseksi
DE59008170D1 (de) Verfahren zur Herstellung mikronisierter bioabbaubarer Partikel.
HUT48268A (en) Process for producing pharmaceutical nukleozide and pharmaceutical compositions containing them
HUT50790A (en) Process for producing new 3,5-dihydroxycarboxylic acids and derivatives thereof, as well as pharmaceutical compositions and intermediates comprising such compounds
HUT46664A (en) Process for producing new dihydropyridineamide derivatives and pharmaceutical compositions comprising these compounds
RU93058177A (ru) Производные пиридона, способ их получения, фармацевтическая композиция и промежуточные соединения синтеза
HUT58094A (en) Process for producing 20,21-dinoreburnamenin derivatives and pharmaceutical compositions comprising such compounds, as well as their intermediates
PT87301A (pt) Process for the preparation of 1,3-dioxanes by products and of pharmaceutical compounds containing them
DE3781879D1 (de) Anthracyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE118004T1 (de) 4-amidino-chroman und 4-amidino-pyrano(3,2- c)pyridinderivate, verfahren zur herstellung und diese enthaltende pharmazeutische zusammenstellungen.
FI890678A (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 1,3-dioksaanialkeenihappojohdannaisten valmistamiseksi
HU904582D0 (en) Process for producing amino-oligohydroxi derivatives and pharmaceutical preparatives containing those compounds
HUT47132A (en) Process for producing new 2beta, 16beta-diamono-androstane derivatives and pharmaceutical compositions comprising such compounds
HUT54682A (en) Process for producing 13-bromine- and 13,14-dibromine-ergoline derivatives and pharmaceutical preparatives containing these compounds
HUT49849A (en) Process for producing ketenedithioacetal derivatives and pharmaceutical compositions comprising these compounds as active ingredient
PT88578A (pt) Process for the manufacture of 2,6-methanopyrrolo-3-benzazocines of intermediates useful for their manufacture and of pharmaceutical compositions containing them
ATE45953T1 (de) Anthracyclinderivate, deren verfahren zur herstellung und deren pharmazeutische zusammensetzung und deren benuetzung als arznei.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 579996

Country of ref document: ES